Rapid and dramatic glucose ‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

The areas of time above range (>180  mg/dL, shown in yellow) almost disappeared immediately after bromocriptine administration. AbstractDopamine receptor agonists are typically used to treat Parkinson ’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor. A 53‐year‐old woman with a history of prolactinoma was referred to Kumamoto University Hospital (Kumamoto, Japan) with poorly controlled type 2 diabetes. Her glycated hemoglobin and serum prol actin levels were increased (8.8% and 160.3 ng/mL, respectively). Bromocriptine, a dopamine D2 receptor agonist, was administered to reduce her serum prolactin level. Because bromocriptine ‐QR (quick release) has been approved for the treatment of type 2 diabetes mellitus in the USA, a continuous glucose monitoring system, FreeStyle Libre Pro, was utilized to examine the effect of bromocriptine on glycemic control. After the initial administration of bromocriptine, glucose levels w ere rapidly and dramatically ameliorated, and the time in range (70–180 mg/dL) improved from<50% to>90% between 1  week before and after the initial administration of bromocriptine.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Case Report Source Type: research